Journal ArticleDOI
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant,Brigitte Mlineritsch,G. Luschin-Ebengreuth,Franz Kainberger,Helmut Kässmann,Jutta Claudia Piswanger-Sölkner,Michael Seifert,Ferdinand Ploner,Christian Menzel,Peter Dubsky,Florian Fitzal,Vesna Bjelic-Radisic,Günther G. Steger,Richard Greil,Christian Marth,Ernst Kubista,Hellmut Samonigg,Peter Wohlmuth,Martina Mittlböck,Raimund Jakesz +19 more
TLDR
A randomised, open-label, phase III, 4-arm trial comparing tamoxifen and goserelin versus anastrozole and zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuant treatment with or without zoledronics acid.Abstract:
Summary Background The Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) bone substudy assesses zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuvant treatment with or without zoledronic acid. The aim of this substudy is to gain insight into bone health in this setting. Methods ABCSG-12 is a randomised, open-label, phase III, 4-arm trial comparing tamoxifen (20 mg/day orally) and goserelin (3·6 mg subcutaneously every 28 days) versus anastrozole (1 mg/day orally) and goserelin (3·6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer. This prospective bone subprotocol measured BMD at 0, 6, 12, 36, and 60 months. The primary endpoint of the bone substudy (secondary endpoint in the main trial) was change in BMD at 12 months, assessed by dual-energy X-ray absorptiometry in assessable patients. Analyses were intention to treat. Statistical significance was assessed by t tests. The ABCSG-12 trial is registered on the ClinicalTrials.gov website, number NCT00295646. Findings 404 patients were prospectively included in the bone substudy and randomly assigned to endocrine therapy alone (goserelin and anastrozole or goserelin and tamoxifen; n=199) or endocrine therapy concurrent with zoledronic acid (goserelin, anastrozole, and zoledronic acid or goserelin, tamoxifen, and zoledronic acid; n=205). After 3 years of treatment, endocrine therapy alone caused significant loss of BMD at the lumbar spine (−11·3%, mean difference −0·119 g/cm 2 [95% CI −0·146 to −0·091], p 2 [−0·076 to −0·030], p 2 [−0·179 to −0·102] vs −9·0%, mean difference −0·095 g/cm 2 [−0·134 to −0·057], p 2 [−0·106 to −0·027], p=0·001; trochanter −4·1%, mean difference −0·03 g/cm 2 [−0·062 to 0·001], p=0·058). Patients who received zoledronic acid had stable BMD at 36 months (lumbar spine +0·4%, mean difference 0·004 g/cm 2 [−0·024 to 0·032]; trochanter +0·8%, mean difference 0·006 g/cm 2 [−0·018 to 0·028]) and increased BMD at 60 months at both sites (lumbar spine +4·0%, mean difference 0·039 g/cm 2 [0·005–0·075], p=0·02; trochanter +3·9%, mean difference 0·028 g/cm 2 [0·003–0·058], p=0·07) compared with baseline. Interpretation Goserelin plus tamoxifen or anastrozole for 3 years without concomitant zoledronic acid caused significant bone loss. Although there was partial recovery 2 years after completing treatment, patients receiving endocrine therapy alone did not recover their baseline BMD levels. Concomitant zoledronic acid prevented bone loss during therapy and improved BMD at 5 years. Funding AstraZeneca (London, UK) and Novartis (Basel, Switzerland).read more
Citations
More filters
Journal ArticleDOI
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant,Brigitte Mlineritsch,Walter Schippinger,G. Luschin-Ebengreuth,Sabine Pöstlberger,Christian Menzel,Raimund Jakesz,Michael Seifert,Michael Hubalek,Vesna Bjelic-Radisic,Hellmut Samonigg,C. Tausch,Holger Eidtmann,Guenther G. Steger,Werner Kwasny,Peter Dubsky,M. Fridrik,Florian Fitzal,Michael Stierer,Ernst Rücklinger,Richard Greil +20 more
TL;DR: The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer.
Journal ArticleDOI
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Harold J. Burstein,Ann Alexis Prestrud,Jerome Seidenfeld,Holly Anderson,Thomas A. Buchholz,Nancy E. Davidson,Karen E. Gelmon,Sharon H. Giordano,Clifford A. Hudis,Jennifer Malin,Eleftherios P. Mamounas,Diana Rowden,Alexander J. Solky,MaryFran Sowers,Vered Stearns,Eric P. Winer,Mark R. Somerfield,Jennifer J. Griggs +17 more
TL;DR: It is recommended that postmenopausal women with hormone receptor-positive breast cancer consider incorporating AI therapy at some point during adjuvant treatment, either as up-front therapy or as sequential treatment after tamoxifen.
Journal ArticleDOI
Breast Cancer Before Age 40 Years
TL;DR: Chemotherapy, endocrine, and local therapies have the potential to significantly impact both the physiologic health-including future fertility, premature menopause, and bone health-and the psychological health of young women as they face a diagnosis of breast cancer.
Journal ArticleDOI
Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
Francesca Greco,María J. Vicent +1 more
TL;DR: Early studies of polymer-drug conjugates for multi-agent therapy revealed the therapeutic potential but raised new challenges that need to be addressed for a successful optimisation of the system towards clinical applications.
Journal ArticleDOI
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant,Brigitte Mlineritsch,Herbert Stoeger,G. Luschin-Ebengreuth,Dietmar Heck,Christian Menzel,Raimund Jakesz,Michael Seifert,Michael Hubalek,Gunda Pristauz,Thomas Bauernhofer,Holger Eidtmann,Wolfgang Eiermann,Guenther G. Steger,Werner Kwasny,Peter Dubsky,Gerhard Hochreiner,Ernst-Pius Forsthuber,Christian Fesl,Richard Greil +19 more
TL;DR: Long-term clinical efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid is assessed, showing persistent benefits with zoledronics acid and support to adjuvant endocrine therapy with premenopausal patients.
References
More filters
Journal ArticleDOI
A new look at the statistical model identification
TL;DR: In this article, a new estimate minimum information theoretical criterion estimate (MAICE) is introduced for the purpose of statistical identification, which is free from the ambiguities inherent in the application of conventional hypothesis testing procedure.
Journal ArticleDOI
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
TL;DR: Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer, especially gynaecological problems and vascular events, but arthralgia and fractures were increased.
Journal ArticleDOI
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
TL;DR: A new general procedure for treatment assignment is described which concentrates on minimizing imbalance in the distributions of treatment numbers within the levels of each individual prognostic factor.
Journal ArticleDOI
Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research
Sundeep Khosla,David B. Burr,Jane A. Cauley,David W. Dempster,Peter R. Ebeling,Dieter Felsenberg,Robert F. Gagel,Vincente Gilsanz,Theresa A. Guise,Sreenivas Koka,Laurie K. McCauley,Joan McGowan,Marc D. McKee,Suresh Mohla,David G. Pendrys,Lawrence G. Raisz,Salvatore L. Ruggiero,David Shafer,Lillian Shum,Stuart L. Silverman,Catherine Van Poznak,Nelson B. Watts,Sook-Bin Woo,Elizabeth Shane +23 more
TL;DR: This report summarizes the findings and recommendations of the task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder.
Journal ArticleDOI
Bone mineral density thresholds for pharmacological intervention to prevent fractures
Ethel S. Siris,Y. T. Chen,Thomas A. Abbott,Elizabeth Barrett-Connor,Paul D. Miller,Lois E. Wehren,Marc L. Berger +6 more
TL;DR: A strategy to reduce overall fracture incidence will likely require lifestyle changes and a targeted effort to identify and develop treatment protocols for women with less severe low bone mass who are nonetheless at increased risk for future fractures.
Related Papers (5)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant,Brigitte Mlineritsch,Walter Schippinger,G. Luschin-Ebengreuth,Sabine Pöstlberger,Christian Menzel,Raimund Jakesz,Michael Seifert,Michael Hubalek,Vesna Bjelic-Radisic,Hellmut Samonigg,C. Tausch,Holger Eidtmann,Guenther G. Steger,Werner Kwasny,Peter Dubsky,M. Fridrik,Florian Fitzal,Michael Stierer,Ernst Rücklinger,Richard Greil +20 more